Its opioid dissed by FDA advisors, S.F. drugmaker abandons program

A rejection of its experimental pain drug Tuesday forced Nektar Therapeutics Inc. to dump the program. In a rare indisputable rejection, two Food and Drug Administration advisory committees voted 27-0 to recommend that the FDA not approve the San Francisco company's oxycodegol, a slow-acting opioid aimed at chronic lower back pain. The FDA isn't required to live by the advisory committees' recommendation, but six hours later Nektar (NASDAQ: NKTR) said it would withdraw its approval request and…

Click to view original post